Applied Therapeutics Net Income
| APLT Stock | USD 0.10 0.00 0.00% |
As of the 25th of February, Applied Therapeutics shows the Mean Deviation of 7.02, standard deviation of 12.45, and Risk Adjusted Performance of (0.14). Applied Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Applied Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 5.418 | Revenue | Earnings Share (0.10) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -95.1 M | -99.8 M | |
| Net Loss | -95 M | -90.3 M | |
| Net Loss | -95.1 M | -99.8 M | |
| Net Loss | (0.68) | (0.72) |
Applied | Net Income | Build AI portfolio with Applied Stock |
The evolution of Net Income for Applied Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Applied Therapeutics compares to historical norms and industry peers.
Latest Applied Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Applied Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Applied Therapeutics financial statement analysis. It represents the amount of money remaining after all of Applied Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Applied Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Applied Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (105.62 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Applied Net Income Regression Statistics
| Arithmetic Mean | (46,857,722) | |
| Coefficient Of Variation | (101.31) | |
| Mean Deviation | 43,812,144 | |
| Median | (16,521,000) | |
| Standard Deviation | 47,472,733 | |
| Sample Variance | 2253.7T | |
| Range | 115.5M | |
| R-Value | (0.89) | |
| Mean Square Error | 495.3T | |
| R-Squared | 0.79 | |
| Slope | (8,376,644) | |
| Total Sum of Squares | 36058.6T |
Applied Net Income History
Other Fundumenentals of Applied Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Applied Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Applied Therapeutics is extremely important. It helps to project a fair market value of Applied Stock properly, considering its historical fundamentals such as Net Income. Since Applied Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Applied Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Applied Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Search Suggestions
| AP | Ampco Pittsburgh | Company |
| APO-PA | Apollo Global Management | Company |
| APBDX | Bond Fund Investor | Mutual Fund |
| APCB | Trust For Professional | ETF |
| APT | Aptos | Cryptocurrency |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionApplied Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Applied Therapeutics reported net income of (105.62 Million). This is 130.95% lower than that of the Biotechnology sector and 250.79% lower than that of the Health Care industry. The net income for all United States stocks is 118.5% higher than that of the company.
Applied Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Applied Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Applied Therapeutics could also be used in its relative valuation, which is a method of valuing Applied Therapeutics by comparing valuation metrics of similar companies.Applied Therapeutics is currently under evaluation in net income category among its peers.
Applied Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Applied Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Applied Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Applied Therapeutics' value.| Shares | Millennium Management Llc | 2025-06-30 | 1.9 M | Qube Research & Technologies | 2025-06-30 | 1.8 M | Marshall Wace Asset Management Ltd | 2025-06-30 | 1.5 M | Adage Capital Partners Gp Llc | 2025-06-30 | 1.2 M | Geode Capital Management, Llc | 2025-06-30 | 968.5 K | Ubs Group Ag | 2025-06-30 | 830.6 K | Goldman Sachs Group Inc | 2025-06-30 | 730.7 K | Deutsche Bank Ag | 2025-06-30 | 622.2 K | Two Sigma Investments Llc | 2025-06-30 | 594.5 K | T. Rowe Price Investment Management,inc. | 2025-06-30 | 18.7 M | Vestal Point Capital Lp | 2025-06-30 | 11.5 M |
Applied Fundamentals
| Return On Equity | -6.8 | ||||
| Return On Asset | -0.88 | ||||
| Operating Margin | (17.97) % | ||||
| Current Valuation | 5.42 M | ||||
| Shares Outstanding | 144.3 M | ||||
| Shares Owned By Insiders | 5.49 % | ||||
| Shares Owned By Institutions | 68.78 % | ||||
| Number Of Shares Shorted | 3.54 M | ||||
| Price To Earning | (7.46) X | ||||
| Price To Book | 7.72 X | ||||
| Price To Sales | 14.86 X | ||||
| Revenue | 455 K | ||||
| Gross Profit | (38.06 M) | ||||
| EBITDA | (104.3 M) | ||||
| Net Income | (105.62 M) | ||||
| Cash And Equivalents | 67.72 M | ||||
| Cash Per Share | 1.41 X | ||||
| Total Debt | 2.79 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 1.49 X | ||||
| Book Value Per Share | (0) X | ||||
| Cash Flow From Operations | (84.31 M) | ||||
| Short Ratio | 0.30 X | ||||
| Earnings Per Share | (0.10) X | ||||
| Target Price | 0.25 | ||||
| Number Of Employees | 28 | ||||
| Beta | 2.08 | ||||
| Market Capitalization | 14.86 M | ||||
| Total Asset | 86.69 M | ||||
| Retained Earnings | (574.21 M) | ||||
| Working Capital | 56.35 M | ||||
| Current Asset | 37.74 M | ||||
| Current Liabilities | 11.19 M | ||||
| Net Asset | 86.69 M |
About Applied Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Applied Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Applied Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Applied Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Applied Stock Analysis
When running Applied Therapeutics' price analysis, check to measure Applied Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Applied Therapeutics is operating at the current time. Most of Applied Therapeutics' value examination focuses on studying past and present price action to predict the probability of Applied Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Applied Therapeutics' price. Additionally, you may evaluate how the addition of Applied Therapeutics to your portfolios can decrease your overall portfolio volatility.